Table 1.
Baseline demographic and clinical and socioeconomic characteristics
| Integrase inhibitor group (n=289) | Protease inhibitor group (n=286) | |
|---|---|---|
| Age (years) | 34 (28–43) | 35 (29–42) |
|
| ||
| Race or ethnic origin | ||
| White | 128 (44%) | 119 (42%) |
| Black | 143 (50%) | 133 (47%) |
| Asian | 9 (3%) | 17 (6%) |
| Hispanic/Latino | 20 (7%) | 24 (8%) |
|
| ||
| Asymptomatic HIV Infection | 235 (81%) | 214 (75%) |
|
| ||
| AIDS | 12 (4%) | 13 (5%) |
|
| ||
| HIV-1 RNA (log10 copies per mL) | 4·46 (4·09–4·97) | 4·56 (4·02–5·00) |
| ≤100 000 | 220 (76%) | 214 (75%) |
| >100 000–400 000 | 44 (15%) | 50 (18%) |
| >400 000 | 25 (9%) | 22 (8%) |
|
| ||
| CD4 cell count (cells per μL) | 344 (246–466) | 370 (244–489) |
| <50 | 7 (2%) | 13 (5%) |
| 50–199 | 42 (15%) | 39 (14%) |
| 200–349 | 97 (34%) | 79 (28%) |
| 350–499 | 83 (29%) | 86 (30%) |
| ≥500 | 60 (21%) | 68 (24%) |
|
| ||
| Positive HBsAg, % | 9% (4%) | 7% (3%) |
|
| ||
| Positive HCV antibody, % | 22% (8%) | 25% (9%) |
|
| ||
| Estimated creatinine clearance (mL/min) | 105·6 (93·0–128·4) | 106·2 (91·8–124·4) |
|
| ||
| Body-mass index (kg/m2) | 24·9 (21·9–29·2) | 24·3 (21·1–28·6) |
|
| ||
| Sexually active | 172 (60%) | 172 (60%) |
| Monogamous partner | 155/172 (90%) | 153/172 (89%) |
| Previous pregnancy | 237 (82%) | 244 (85%) |
|
| ||
| History of sexually transmitted disease | 76 (26%) | 80 (28%) |
|
| ||
| History of anxiety/depression | 51 (18%) | 60 (21%) |
|
| ||
| Use of contraception | 236 (82%) | 245 (86%) |
| Oral contraceptive | 22 (8%) | 27 (9%) |
| Abstinence | 73 (25%) | 70 (25%) |
| Condom | 155 (54%) | 148 (52%) |
| Intrauterine device | 14 (5%) | 18 (6%) |
| Diaphragm/cervical cap | 50 (17%) | 55 (19%) |
| Injectable/implant | 29 (10%) | 31 (11%) |
| Tubal ligation | 21 (7%) | 27 (9%) |
|
| ||
| Education | ||
| Less than high school | 118 (41%) | 106 (37%) |
| High school graduate | 40 (14%) | 64 (22%) |
| 4 year college degree | 23 (8%) | 14 (5%) |
|
| ||
| Working/employed | 193 (67%) | 185 (65%) |
|
| ||
| Marital Status | ||
| Single | 88 (30%) | 91 (32%) |
| Married | 109 (38%) | 104 (36%) |
| Divorced | 27 (9%) | 39 (14%) |
| Widowed | 26 (9%) | 26 (9%) |
| Domestic partner | 24 (8%) | 13 (5%) |
|
| ||
| Number of children in household | ||
| None | 136 (47%) | 135 (47%) |
| 1 | 80 (28%) | 77 (27%) |
| 2 | 33 (11 %) | 37 (13%) |
| ≥3 | 40 (14%) | 37 (13%) |
|
| ||
| Recreational substance use | ||
| Tobacco | 69 (24%) | 73 (26%) |
| Alcohol | 140 (48%) | 154 (54%) |
| Drug | 6 (2%) | 12 (4%) |
Data are median (IQR), n (%), or median, unless otherwise indicated. Integrase inhibitor regimen was elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate; protease inhibitor regimen was ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate. HBsAg=hepatitis B surface antigen. HCV=hepatitis C virus.